Journal
EUROPEAN JOURNAL OF CANCER
Volume 152, Issue -, Pages 215-222Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2021.05.003
Keywords
Abiraterone; Enzalutamide; Geriatric oncology; Metastatic castration-resistant prostate cancer; Toxicity; PSA response rate; Survival
Categories
Funding
- Prostate Cancer Foundation Young Investigator Award
Ask authors/readers for more resources
A comparison study of AA and enzalutamide in patients with mCRPC aged >= 80 years showed that enzalutamide had a higher PSA response rate and longer time to progression, although there were more dose reductions and treatment discontinuations in the enzalutamide group.
Background: Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population. Objective: To compare the clinical efficacy and tolerability of AA versus enzalutamide in patients >= 80 years with mCRPC. Design, setting and participants: A retrospective propensity-weighted comparative cohort study of first-line AA versus enzalutamide among patients with mCRPC aged >= 80 years. Outcome measurements and statistical analysis: Inverse probability treatment weights based on propensity scores were generated to assess the treatment effect of AA versus enzalutamide on time to PSA progression (TTPP), time to progression (TTP) (first of PSA/radiographic/clinical progression) and overall survival using a weighted Cox proportional hazards model. PSA response rate (PSA RR) was compared between groups using X-2. Results and limitations: One hundred fifty-three patients received AA, and 125 received enzalutamide. Enzalutamide was associated with higher PSA RR (61.6% vs 43.8%, P < 0.004), and TTP (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.50-0.88, P = 0.01) but not TTPP (HR 0.73, 95% CI 0.53-1.01, P = 0.06). There were significantly more dose reductions with enzalutamide (22.9% vs 44.8%, P > 0.001) but there was no interaction between median proportion of full dose received and TTPP or TTP for either drug. Rates of treatment discontinuation (for reasons other than progression) were also significantly different between AA and enzalutamide (28.8% vs 40.8%, respectively, P = 0.04). The most common reason for dose reductions and discontinuation of enzalutamide was fatigue (30.4% and 5.6%, respectively). Conclusions: Despite more dose reductions and a higher treatment discontinuation rate, enzalutamide was associated with a higher PSA RR and longer time to progression, than AA. Given that clinical outcomes were not adversely impacted by decreased treatment exposure, dose modification may be a useful treatment strategy to balance toxicity and tolerance. (C) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available